Arcturus Therapeutics Shares Surge on Thermo Fisher Collaboration for Cystic Fibrosis mRNA Therapy
Arcturus teams up with Thermo Fisher to develop a new cystic fibrosis mRNA drug, boosting shares on hopes for faster progress.
/ 4 items
#ARCT↓
Arcturus Therapeutics Stands Out in mRNA Space – B. Riley Initiates Buy with $22 Price Target
B. Riley starts coverage on Arcturus Therapeutics with Buy, praising its standout lipid-enabled mRNA platform for cystic fibrosis (ARCT-032) and OTC deficiency (ARCT-810) programs.
Roth Capital Starts Coverage on Arcturus Therapeutics With Buy Rating
Roth Capital initiates coverage of Arcturus Therapeutics with a Buy rating and $20 price target, citing undervaluation and strong rare disease pipeline potential.
Arcturus Shares Plunge After Mixed Results in Cystic Fibrosis Spray Trial
Arcturus Therapeutics shares drop sharply after interim trial data on its inhaled mRNA therapy for cystic fibrosis show mixed results—some signs of mucus reduction but limited lung function improvement.